Optical molecular imaging developer raises $3.1M in Series A funding
Optical molecular imaging technology developer Lightpoint Medical has raised $3.1 million in Series A financing.
Optical molecular imaging technology developer Lightpoint Medical (Rickmansworth, Hertfordshire, England) has raised $3.1 million (£2 million) in Series A financing. Investors included Oxford Technology and business angel networks Cambridge Capital Group, London Business Angels, Envestors, Ruffena Capital, and crowdfunding platform SyndicateRoom.
Lightpoint Medical's technology, which is based on Cerenkov luminescence imaging, can help detect cancer in real time during surgery and reduce the need for repeat operations. The company has clinical trials underway in breast, prostate, and stomach cancers.
The company will use the investment funding to help bring its LightPath specimen analyzer for intraoperative tumor margin assessment and EnLight molecular imaging fiberscope to the U.S. and European markets in 2015.